Results 241 to 250 of about 175,835 (341)

Protective Role for Itaconate During Inhaled Allergen Challenge

open access: yesAllergy, EarlyView.
Itaconate levels decrease in sputum following allergen inhalation in mild asthmatics, suggesting a dynamic metabolic response to airway challenge. Genetic deletion of Acod1 in mice did not alter airway inflammation or remodelling in response to chronic HDM exposure.
Gesa J. Albers   +16 more
wiley   +1 more source

The Therapeutic Potential of Farm Dust Extracts in a Mouse Model of Eosinophilic Inflammation

open access: yesAllergy, EarlyView.
Farm dust extract (FDE) treatment reduces airway eosinophilia, mucus overproduction, and MHC‐II expression on DCs, limiting antigen presentation and Th2 inflammation. It increases PD‐L1 on DCs, promoting T cell deactivation. Additionally, FDE enhances Tregs and upregulates CTLA‐4, reinforcing suppression.
Rabia Ülkü Korkmaz   +16 more
wiley   +1 more source

Allergic Rhinitis and Its Impact on Asthma (ARIA)‐EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments

open access: yesAllergy, EarlyView.
ABSTRACT Background Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI‐endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024 ...
Bernardo Sousa‐Pinto   +252 more
wiley   +1 more source

First-in-human intranasal [<sup>13</sup>N]oxytocin PET: evaluation of feasibility, biodistribution, and radiation dosimetry. [PDF]

open access: yesEJNMMI Res
Winterdahl M   +6 more
europepmc   +1 more source

“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps

open access: yesAllergy, EarlyView.
This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2‐CRSwNP by assessing how many patients maintain disease control with once‐every‐12‐weeks (Q12W) dosing and comparing clinical characteristics of super‐responders and excellent responders. Tapering of dupilumab to Q12W appears feasible in super‐responding patients.
P. E. Vonk   +13 more
wiley   +1 more source

Long‐Term Effect of Allergen Immunotherapy in Responder Local Allergic Rhinitis Patients: Symptom Control, and Prevention of Asthma and Allergic Sensitizations

open access: yesAllergy, EarlyView.
LAR patients who respond to AIT during the first year and are treated for two more years continue improving (less symptoms and medication intake) during the following seven years. AIT prevents the onset of asthma and allergic sensitizations in responder LAR individuals during the seven years following discontinuation.
Almudena Testera‐Montes   +9 more
wiley   +1 more source

Innovative approach in Parkinson's targeting via berberine-loaded mucoadhesive surface-modified liposomes: a multi-faceted study. [PDF]

open access: yesBMC Pharmacol Toxicol
Nematalla HA   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy